非小细胞肺癌重组人血管内皮抑素治疗与循环内皮祖细胞水平研究

Circulating endothelial progenitor cells in the peripheral blood of advanced non-small cell lung cancer after antiangiogenic therapy

目的分析晚期非小细胞肺癌（NSCLC）患者抗血管生成治疗前后外周血中循环内皮祖细胞（cEPCs）的变化，探讨cEPCs在NSCLC中的应用价值。方法采用吉西他滨＋顺铂化疗（GP）方案联合重组人血管内皮抑素（实验组）及单用GP方案（对照组）治疗晚期NSCLC患者52例，流式细胞法检测治疗前后cEPCs水平。结果实验纽组临床有效率为44．0％，对照纽为25．9％（P=0．245）；实验纽临床受益率为80．0％，对照组为51．8％（P=0．044）；实验组cEPCs平均下降（0．041±0．044）％，对照组平均下降（0．011±0．047）％（P〈0．05）。结论化疗联合抗血管生成治疗治疗晚期NSCLC优于单用化疗，cEPCs可以作为有效的疗效预测指标。

Objective To investigate the changes and clinical value of circulating endothelial progenitor cells （eEPCs） in the peripheral blood of advanced non-small cell lung cancer （NSCLC） pa- tients. Methods Fifty-two advanced NSCLC patients were randomly divided into the experimental group （treated with GP plus recombinant human endostatin）and control group（treated with GP alone）.The levels of cEPCs pre-treatment and post- treatment were measured by flow cytometry. Results The response rate and benefit rate was 44. 0% ,80.0% in the experimental group,and 25.9% , 51.8% in the control group, （P = 0. 245 and P = 0. 044, respectively）. The number of eEPCs decreased by （0. 041 ±0. 044） % in the experimental group, （0.011 ± 0. 047 ） % in the control group （P 〈 0.05 ）. Conclusions Chemotherapy combined with antiangiogenic therapy is superior to chemotherapy alone in treatment of NSCLC. CEPCs may act as an effective biomarker in predicting the efficacy of antiangiogenic therapy.